N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes [Corrigendum]

Figures & data

Table 1 Characteristics of subjects with and without diabetic complications

	Case subjects*	Control subjects	P
n	217	60
Age (years)	63.4±12.0	54.1±13.6	<0.0001
Diabetes duration (years)	9 (3~17)	4 (1~11)	0.0029
Males (%)	60.8%	70.0%	0.1933
BMI (kg/m^2)	26.3±4.9	25.9±5.3	0.5466
HbA1c (%)	8.7±2.0 (71.6)	8.5±2.3 (69.4)	0.4404
SBP (mmHg)	136.4±19.6	130.3±16.8	0.0270
DBP (mmHg)	79.0±12.5	77.7±10.4	0.4525
Total cholesterol (mg/dL)	195.1±37.9	199.0±49.8	0.5918
LDL cholesterol (mg/dL)	117.2±33.6	122.8±37.7	0.2733
HDL cholesterol (mg/dL)	55.1±16.1	56.9±17.3	0.4528
Triglycerides (mg/dL)	140 (104~214)	151 (107~231)	0.7500
NT-proBNP (pg/mL)	59 (26~140)	33 (16~58)	<0.0001
Smoking (%)	24.2%	24.4%	0.5040
Albuminuria (μg/min)	24.9 (9.0~92.8)	8.2 (5.4~15.7)	<0.0001
PWVR (cm/sec)	1,788±431	1,504±301	<0.0001
PWVL (cm/sec)	1,813±568	1,522±303	0.0003
ABIR	1.12±0.14	1.14±0.08	0.4128
ABIL	1.11±0.14	1.14±0.09	0.0939
LVH (mm)	26.1±8.7	24.9±6.5	0.3652
eGFR (mL/min/1.73m^2)	71.6±23.5	79.8±20.4	0.0147

Notes: Data are mean ± SD.

* Presence of any of diabetic complications (DMR, nephropathy, DSN, CVD, and PAD). P-values in bold were demonstrated to have adequate effect size.

Abbreviations: BMI, body mass index; HbA_1c, hemoglobin A_1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; NT-proBNP, N-terminal fragment of probrain natriuretic peptide; IMTL, intima media thickness of left carotid; IMTR, intima media thickness of right carotid; PWV, pulse wave velocity; ABI, ankle brachial index; LVH, left ventricular hypertrophy; eGFR, estimated glomerular filtration rate; R, right; L, left; SD, standard deviation; CVD, cardiovascular disease; PAD, peripheral artery disease; DMR, diabetes mellitus retinopathy; DSN, distal sensory neuropathy.